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Abstract
Deleterious neurochemical, structural, and behavioral alterations are a seemingly unavoidable
aspect of brain aging. However, the basis for these alterations, as well as the basis for the
tremendous variability in regards to the degree to which these aspects are altered in aging
individuals, remains to be elucidated. An increasing number of individuals regularly consume a
diet high in fat, with high fat diet consumption known to be sufficient to promote metabolic
dysfunction, although the links between high fat diet consumption and aging are only now
beginning to be elucidated. In this review we discuss the potential role for age-related metabolic
disturbances serving as an important basis for deleterious perturbations in the aging brain. These
data not only have important implications for understanding the basis of brain aging, but also may
be important to the development of therapeutic interventions which promote successful brain
aging.
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What causes the brain to age?
Aging is a largely hypothetical construct that has a wide range of working definitions. For
example, aging can be defined as the collection of changes that increase over time to
promote morbidity and consequently render individuals progressively more likely to die
(Medawar PB 1952). Alternatively, aging has been defined as a gradual deterioration of
physiological function with age (Partridge and Mangel 1999). With regards to the aging of
tissues, aging can be defined as an intrinsic and potentially irreversible set of processes
which result in a loss of viability and increased vulnerability (Comfort A 1964). With
specific regards to the brain, it is well established that as the result of increased
chronological aging the brain undergoes numerous alterations at the molecular, cellular, and
structural level. In this review we will discuss the potential roles of metabolic perturbations
such as obesity and insulin resistance, serving as modulators for multiple aspects of brain
aging. Additionally, the links between high fat diet consumption and metabolic dysfunction
are discussed in the context of brain aging.
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Molecular and cellular changes in the aging brain
In regards to brain aging some of the most studied molecular and cellular changes can be
grouped as being alterations in neurotransmitter signaling, increases in inflammatory
signaling, and increases in oxidative stress (Fig. 1). Each of these is discussed below and in
later sections discussed in the context of age and diet-induced metabolic dysfunction.
Changes in neurotransmitter signaling within the aging brain
In the aging brain there are well documented changes in multiple aspects of neurotransmitter
signaling. For example, declines in the levels of neurotransmitters such as acetylcholine are
well documented in the aging brain (Bartus et al. 1982;Gibson and Peterson 1981;Gibson et
al. 1981;Ogawa 1989;Terry, Jr. and Buccafusco 2003;Vannucchi and Pepeu 1987;Wu et al.
1988) and age-related neurodegenerative disorders such as Alzheimer's disease (AD) (Bartus
et al. 1982;Ogawa 1989;Terry, Jr. and Buccafusco 2003;Jia et al. 2004;Tohgi et al. 1994).
Additionally, the levels and density of key neurotransmitters such as dopamine have been
demonstrated to be decreased in the aging brain (Bannon and Whitty 1997;Carlsson
1987;Meng et al. 1999;Volkow et al. 1996;Wang et al. 1998). In contrast, studies indicate a
role for excessive glutamate signaling occurring in the aging brain, especially in age-related
disorders such as AD, culminating in the development of neuron death through
excitotoxicity (Coyle et al. 1981;Coyle and Puttfarcken 1993;Hynd et al. 2004;Mattson et
al. 1992;Mattson et al. 1995b;Mattson et al. 1995a;Sattler and Tymianski 2000). Together,
these data point to gross imbalances in neurotransmitters occuring during brain aging and
age-related diseases of the brain.
In addition to having an imbalance in the level of neurotransmitters within the brain,
additional studies have documented that there is a deleterious change in the levels of key
neurotransmitter receptors during aging. For example, it has been demonstrated that the
glutamate receptor subunits (NR1, NR2A, and NR2B), and the AMPA receptor decline with
age (Adams et al. 2008;Clark et al. 1992;Gazzaley et al. 1996;Morrison and Hof
1997;Sonntag et al. 2000;Wenk and Barnes 2000;Magnusson 2000;Eckles-Smith et al.
2000;Clayton and Browning 2001;Clayton et al. 2002;Shi et al. 2007;Newton et al. 2008).
Similarly, a number of studies have also reported significant age-related decreases in the
levels of dopamine receptors D1, D2, and D3 (Wang et al. 1998;Kaasinen et al. 2000;Iyo
and Yamasaki 1993;Rinne et al. 1990;Wong et al. 1984). Decreasing levels of different
serotonin receptors have also been shown to occur with age. Particularly, humans studied by
positron emission tomography have shown that S2 serotonin receptors in the caudate
nucleus, putamen, and frontal cerebral cortex decline with age (Wong et al. 1984).
Regarding the levels of cholinergic receptors, however, the effects of aging are still unclear.
Most studies seem to agree that there is a decrease in muscarinic binding in rodent aging
brain, but there is controversy as to which regions show a significant reduction in receptor
density (James and Kanungo 1976;Freund 1980;Morin and Wasterlain 1980;Lippa et al.
1981;Pedigo, Jr. et al. 1984). Taken together, these data point to disturbances in both
neurotransmitters and neurotransmitter receptors occurring in the aging brain.
Increases in inflammatory signaling within the aging brain
Increased levels of inflammatory signaling are necessary for maintaining the function of all
tissues, including the brain. However, in aging the brain appears to undergo at least three
negative perturbations in inflammatory signaling and immune function. The first of these
negative alterations is the presence of a chronic elevation in the levels of inflammatory
signaling. Increases in multiple aspects of inflammatory signaling have been reported with
aging including increased levels of tumor necrosis factor (TNF)-α, interleukin (IL)-1, and
IL-6 (Spulber and Schultzberg 2010;Terao et al. 2002;Tha et al. 2000;Ye and Johnson
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1999). Furthermore, studies have linked increases in each of these factors to the
development of neuropathology and neuronal dysfunction in the aging brain (Griffin et al.
1995;Patterson 1995;Strauss et al. 1992). Additionally, the levels of cyclooxygenase and
lipoxygenase, and their corresponding prostanoids and eicosanoids are known to be
chronically increased during brain aging (Leone et al. 2007;Manev et al. 2000;Qu et al.
2000;Uz et al. 1998).
In addition to having a sustained increase in the basal levels of inflammatory signaling,
aging is also known to impair the coordinated nature of the immune response (Desai et al.
2010;Giunta 2008). In this model, multiple aspects of an immune response (time required to
mount a response, the extent to which the response is activated, and the rapidity to which the
response is downregulated following the triggering event) are adversely affected by age.
This promotes a more inefficient and ineffective inflammatory signaling within aging tissues
such as the brain. Lastly, aging appears to alter the magnitude of peripheral immune cell
infiltration into the brain following injury (Bolton and Perry 1998). Presumably, these cells
contribute to the modulation of resident immune signaling within the aging brain, although
the potential role of this observation to age-related brain inflammation remains to be fully
elucidated.
Increases in oxidative stress within the aging brain
Oxidative stress occurs when the levels of oxidative damage reach a point that they promote
the development of cellular and/or tissue dysfunction (Ding et al. 2006;Calabrese et al.
2010). An increase in oxidative damage to proteins, lipids, nucleic acids, and sugars in the
aging and AD brain is well documented (Adelman et al. 1988;Berlett and Stadtman
1997;Cai et al. 1996;Finkel and Holbrook 2000;Gabbita et al. 1998;Good et al.
1996;Nunomura et al. 1999;Perry et al. 1998;Sayre et al. 1997;Smith et al. 1996;Sohal et al.
1995;Stadtman and Levine 2000;Stadtman and Oliver 1991). Furthermore, studies have
demonstrated that each of these forms of oxidative damage is sufficient to result in
decreased function of essential proteins and organelles, and thereby contributing to the
development of brain aging. Studies on the levels and activity of antioxidants and
antioxidant enzymes in the aging and AD brain have demonstrated a mixed bag of results
(Calabrese et al. 2000;Calabrese et al. 2003;Calabrese et al. 2004;Calabrese et al.
2006;Droge and Schipper 2007;Kitani et al. 2001;Maier and Chan 2002;Massaad et al.
2009;Navarro and Boveris 2008;Schmitt-Schillig et al. 2005) and it remains unclear to what
extent decreased levels of antioxidants may drive age-related increases in oxidative stress in
the brain. Perhaps most importantly for the purposes of this review, the oxidative stress has
been implicated in mediating the effects of neurotransmitter dysregulation and increased
inflammatory signaling within the aging brain. Together, these data highlight a model for
interplay between each of these cellular processes and the modulation of brain aging.
Structural changes in the aging brain
In the context of brain aging the best studied structural changes include synaptic changes,
white matter changes, and vascular changes. Each of these changes is outlined below, and
then later in the review is discussed in the context of aging and metabolic perturbations
below.
Synaptic changes
Studies have documented an aging-related decrease in synaptic number occurring in specific
domains within both experimental animal studies as well as studies of human brains
(Bertoni-Freddari et al. 2006). However, the size of these synapses has been found to be
increased in these experimental settings (Bertoni-Freddari et al. 1996;Bertoni-Freddari et al.
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1992;Bertoni-Freddari et al. 1990). In both normal aging and AD brains, a negative
correlation has been found between synapse number and synapse size. This appears to
potentially be a compensatory response to minimize the effects of decreased synapse
number, specifically to attempt to maintain the flux of information at the junctional zones,
and to stabilize the synaptic contact per unit area (Scheff et al. 1990). However, ultimately
the ability of the cortex to compensate seems to be exceeded and promote a decline in
function (DeKosky and Scheff 1990).
The mechanisms responsible for synaptic changes during aging and AD are not clearly
established. However, it has been demonstrated that oxidative stress may contribute to the
pathophysiology of aging. However, the contribution of oxidative stress to the regulation of
synaptic function is clearly complex. For example, it has been shown that superoxide is
necessary for synaptic plasticity and memory in young animals (Klann et al. 1998;Klann
1998;Knapp and Klann 2002;Thiels and Klann 2002;Thiels et al. 2000), while chronically
elevated levels of superoxide likely contribute to synaptic dysfunction during aging (Hu et
al. 2006).
White matter changes
Through the use of neuroimaging technologies considerable advances have been made in
our understanding of how white matter is altered in the aging brain. For example, regional
differences in regards to age-related susceptibilities in white matter loss are known to occur
(Guttmann et al. 1998;Hsu et al. 2008;Kennedy and Raz 2009;Lee et al. 2009), with
prefrontal white matter observed to be most sensitive to the effects of aging (Gunning-Dixon
et al. 2009). In addition to changes in white matter density, it is known that aging is
associated with an increase in white matter lesions (Adami et al. 2008;Barber et al.
1999;Bugalho et al. 2007;Launer 2003;Roman 2004). These deleterious perturbations in
connectivity throughout the brain are presumed to contribute to impairments in brain
function. Despite our progress in being able to detect and measure white matter changes,
there are two questions that need to be answered in this research area. Firstly, the role of
white matter structural alterations as mediators of cognitive disturbances in the aging brain
remain to be clarified beyond the point of correlation studies. Secondly, the mediators of
white matter changes remain to be elucidated, although a role for metabolic disturbances as
mediators of white matter pathology is clearly emerging.
Vascular changes
Aging, as well as many neurodegenerative disorders, are associated with structural and
functional alterations of the cerebral vascularization (Aguero-Torres et al. 2006;Behrendt
and Ganz 2002). Aging is characterized by a loss of elongation in endothelial cells,
decreased number of endothelial mitochondria, and progressive impairment in endothelium-
dependent vasodilation (Brandes et al. 2005;d'Alessio 2004;Finch 2005). Additionally,
aging is associated with cerebral blood flow dysregulation and hypoperfusion, abnormal
angiogenesis and remodeling, all of which may promote neuronal injury and neuron death
(de la Torre 2004;Xiao et al. 2004). It is thought that an augmented production of pro-
inflammatory cytokines and vasoactive molecules could be the responsible of the cognitive
decline, potentially through a mechanism of suppression of cerebral blood flow and
amplification of cellular stress (Zlokovic 2005).
Another feature of senescent endothelial cells is the increased generation of endothelial
adhesion molecules (d'Alessio 2004), markers of endothelial inflammation. Increased levels
of blood adhesion molecules have been reported in several brain disorders, namely
atherosclerosis, ischemic stroke, cerebrovascular disease and AD (Fassbender et al.
1999;Frohman et al. 1991;Roher et al. 2004). In addition, soluble intracellular adhesion
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molecule-1 (sICAM-1) has been shown to be present in high levels in cerebrospinal fluid of
individuals with inflammatory diseases of the central nervous system, and it has been
suggested that cerebral endothelial cells are the primary source of sICAM-1 (Roher et al.
2004). This raises the possibility for molecules such as sICAM-1 contributing to vascular
reactivity in the aging brain.
An increase in blood brain barrier (BBB) permeability has been documented to occur during
aging in healthy individuals. Morphological changes of BBB have been also shown in
rodent models of aging (Hosokawa and Ueno 1999). Since some of these models exhibit
increased oxidative stress at an early age (Yasui et al. 2003) prior to the development of
other pathological features, it has been suggested that alterations in BBB could be promoted
via oxidative stress-mediated mechanisms. On the other hand, it has been demonstrated that
hypertension, a common feature of older people, can induce BBB alterations (Nag and Kilty
1997;Baumbach and Heistad 1988). Taken together, these findings highlight the complexity
in understanding the relationship between oxidative stress and morbidities such as
hypertension, in regulating the biological aging of the brain.
Variability in rates and extent of brain aging
While it is clear that chronological aging promotes a generalized aging phenotype in the
brain, it is equally clear that there is dramatic and significant variability in both the rate and
severity of such alterations. For example, studies in humans document that there is
considerable variability in regards to deterioration in cognitive performance with advancing
age (Williams et al. 2005;Hultsch et al. 2002). Since variability at the performance level
could be reflecting variations and alterations at a cellular and system level in the brain,
understanding the basis for this observation is likely important to understanding the basis of
brain aging, and developing interventions for promoting successful brain aging.
Our laboratory, as well as numerous other laboratories, believes there is an important role
for age-related metabolic perturbations in mediating not only brain aging, but also in
explaining the basis for the variability in the rates of brain aging. There is mounting
evidence for metabolic dysfunction, in particular conditions such as obesity and insulin
resistance, as significant contributors to the aging of modern westernized societies.
It is well known that aging is associated with the progressive development of generalized
insulin resistance (DeFronzo 1981;Elahi et al. 2002), inhibition of lipolysis (Kumar et al.
1999;Miller and Allen 1973;Nyberg et al. 1976) and a loss in hepatic control of glucose
production (Gupta et al. 2000) and triglyceride secretion (Bravo et al. 1996). Cumulatively,
each of these manifestations is sufficient to promote an increase in a number of morbidity
factors including cardiovascular and cerebrovascular diseases, gastrointestinal and
respiratory alterations, cancer, and cognitive decline and dementia (Haslam and James
2005;Perlmuter et al. 1988;Qiu et al. 2007). Moreover, people from countries with
traditionally higher mean lifespan are known to undergo an increase in a number of
morbidities after changing their nutritional intake towards energy-rich diets. However, the
availability of pharmacological treatments for these morbidities has allowed for these
deleterious morbidities to not significantly decrease lifespan in the population (Picard and
Guarante, 2005). Despite such progress, it remains unclear whether pharmacological
management of metabolic disorders (obesity, insulin resistance, etc.) is able to also preserve
brain function as these same individuals age.
Age-related neurologic manifestations include sensory deficits (taste, smell, vibration,
vision, and hearing), disturbances in sensing pain, motor dysfunction (altered gait and
posture), sleep disturbances, and impaired memory and cognition. For example, aging
promotes the slowing of central processing and therefore may prolong the time it takes to
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complete tasks. Declines in motor strength, reflex responses, and reaction time with aging
are related to sensori-motor changes. Changes associated with aging also include mild
forgetfulness, a decrease in vocabulary, and learning difficulties (Braun and Anderson
2006). These changes typically occur by the seventh decade of life, but have a great deal of
heterogeneity and variability in regards to the severity of dysfunction which is observed in
elderly individuals (McClearn 1997). While the basis for the variability in brain aging is not
known, one possible mediator is metabolic dysfunction, with increased levels of dietary fat
intake serving as a potential mediator of metabolic dysfunction. For example, high-fat diets
are known to be sufficient to promote insulin resistance and obesity in both humans and
rodents (Buettner et al. 2007;Damjanovic and Barton 2008;Oakes et al. 1997;Tschop and
Heiman 2001). What is less known is what effect high-fat diets have on aging, particularly
brain aging. With the intersection of an increasing aging and obese society, that increasingly
regularly consumes a high fat diet, it is clear that understanding the impact of diet-induced
metabolic perturbations on the aging brain is of mounting clinical importance. The possible
contribution of metabolic dysfunction as a modulator of brain aging raises the possibility
that factors such as diet may be centrally linked to the regulation of brain aging. In
particular, diet-induced metabolic dysfunction likely serves as a pro-aging stimulus for
multiple aspects of brain biochemistry and physiology. Interestingly, several clinical and
epidemiological studies, as well as experimental evidence in rodents, suggest that the
presence of Western diet-induced metabolic dysfunction is sufficient to promote cognitive
decline and even dementia, thus accelerating the normal process of aging.
Several abnormalities of carbohydrate and lipid metabolism have been commonly observed
to increase in Western societies with age, namely insulin resistance, hyperglycemia,
hyperinsulinemia, dyslipemia, triglyceridemia, and free fatty acid alterations (Astrup et al.
2008;Bullo et al. 2007;Matia et al. 2007;Pasinetti and Eberstein 2008;Steemburgo et al.
2007). However, it is not yet completely understood whether these alterations become
manifest as a consequence of the molecular mechanisms operating in the aging process or as
a result of the influence of many cultural/environmental factors such as diet and a decrease
in physical activity (Paolisso et al. 1995).
In the context of brain aging metabolic dysfunction must be understood not only in terms of
diabetes but also in terms of pre-diabetic states where individuals exhibit hyperinsulemia but
remain euglycemic. A high concentration of circulating insulin (hyperinsulinemia) may
represent a failure in insulin metabolism as well as a compensatory response to insulin
resistance. In either case, hyperinsulinemia is correlated with insulin resistance in pre-
diabetic individuals (Howard et al. 1998;Laakso 1993). At this point it is worth to mention
that many studies have reported that the elderly are more insulin resistant that young
individuals (Chen et al. 1985;Coon et al. 1992;DeFronzo 1979;Ferrannini et al.
1996;O'Shaughnessy et al. 1992;Rowe et al. 1983), although this point remains
controversial (Ahren and Pacini 1998;Boden et al. 1993;Broughton et al. 1991;Dechenes et
al. 1998;Pacini et al. 1988). Important to take into account is that several factors may
influence insulin action and secretion, including the degree and type of obesity (Peiris et al.
1986), level of fitness (Kirwan et al. 1993;Miller et al. 1994), and circulation hormone
profiles (Nielsen et al. 1997;Rizza et al. 1982a;Rizza et al. 1982b). Additionally, some
studies have shown that central obesity (increased waist-to-hip ratio) is associated to insulin
resistance and aging. Furthermore, the intra-abdominal fat depot in central-obesity has been
postulated to contribute most to the development of insulin resistance, and therefore the
insulin resistance observed in aging may be related more to changes in body composition
during aging than to aging per se. Moreover, intra-abdominal fat has been postulated to be
the most metabolically active of the adipose depots and correlates with insulin resistance and
age in healthy nondiabetic individuals regardless of gender and after controlling for obesity
(Cefalu 2001;Cefalu et al. 1995).
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Adiposity
Adipose tissue has long been considered as a mere energy-store but is increasingly
appreciated for its roles in participating in several physiological events such as
inflammation, angiogenesis, hypertension, and vascular homeostasis (Fruhbeck 2008).
Moreover, the adipose tissue synthesizes and secretes a large number of factors collectively
termed “adipokines” (Fruhbeck 2008). More than 50 different adipokines have been
identified and characterized for their role in influencing energy homeostasis and feeding
behaviour (Ahima and Osei 2008). However, an increasing number of studies have
identified that adipokines may play a role in mediating long-term potentiation,
neuroprotection, and neuroinflammation.
A major role for adipose tissue (adipocytes) is to sequester and store circulating lipid, which
protects other cells and tissues in the body form the cytotoxic effects of free fatty acids in
the circulation. Failure of adipocytes to effectively remove free fatty acids from the
circulation is believed to contribute to a variety of health complications including
hypertension, atherosclerosis, and ultimately the development of metabolic syndrome
(Fagot-Campagna et al. 1998;Moller and Kaufman 2005;Smith and Wilson 2006;Wang et
al. 2008). Conversely, the deposition of adipose/lipid into muscle, liver, or bone marrow is
known to promote not only metabolic syndrome but localized tissue dysfunction (Kuk et al.
2009). Therefore, it is clear that adipocytes perform essential functions for the overall well
being of individuals, but it is equally clear that adipose in the incorrect places or in excessive
quantity also negatively impacts the health of an individual.
Aging is known to impair the ability of adipocytes to sequester free fatty acids, and promote
the release of pro-inflammatory signals from adipose tissue. Many studies have suggested
that the decline in specific adipose depots is due to a decrease in adipocyte size and not a
reduction in number. Additional studies have demonstrated that aging impairs the process of
adipocyte differentiation resulting in an increase in more highly reactive preadipocytes.
Preadipocytes do not have the capacity to sequester free fatty acids from the circulation to
the same degree as mature adipocytes, and an age-related increase in preadipocytes may
therefore result in promotion of adverse events in regards to the regulation of circulating
lipids. Taken together, these studies strongly suggest that aging has direct and complex
effects on adipose tissue including a redistribution of adipose depots as well as fundamental
alterations in the cell biology of adipocytes, which together may promote metabolic
dysfunction and inflammatory signaling throughout the body.
An increase in visceral adiposity is a common feature of aging, and epidemiological
evidence supports its role as a prominent risk factor for insulin resistance, diabetes, and
mortality from atherosclerotic cardiovascular disease (Ferrannini et al. 1997;Fujimoto et al.
1999;Lamarche 1998;Shimokata et al. 1989;Cefalu et al. 1995). Typically, elderly people
have a lighter body weight as compared to younger individuals but increased waist
circumference, consistent with elevated levels of abdominal adipose tissue. It has been
observed that a complex relationship exists between aging, obesity and increased visceral fat
which is not always sufficient to promote insulin resistance (Carr et al. 2004). It has been
reported that caloric restriction extends life in a variety of species and decreases the
development of most age-related diseases, and it is believed that these effects may be due to
the ability of dietary restriction to reduce fat stores, especially visceral fat. In addition, the
removal of visceral fat in rats has demonstrated to improve insulin action, delay the onset of
age-dependent insulin resistance, glucose intolerance and diabetes, as well as increase in
mean and maximum lifespan in rodent models of obesity and diabetes (Barzilai et al.
1999;Gabriely et al. 2002). Visceral fat removal has shown to improve metabolism even
without any changes in body weight, fat mass, and lean body mass (Gabriely et al. 2002). It
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is thought that surgical removal of visceral fat depots disrupts a cross-talk between fat
depots and multiple sites within the body (Wang et al. 1999).
The issue of adiposity itself in aging is a complex biological problem to study. For example,
total fat mass is known to peak at middle age in both humans and rodents, which is followed
by a precipitous decline with advancing age. However, the decline in fat mass with age does
not coincide with a decrease in percent body fat because lean muscle mass is also decreased
with age. Therefore, body mass index and other such measures do not do an accurate
identification of the dramatic increase in ectopic fat and visceral fat deposition that occurs in
aging. Additionally, it is poorly understood how such changes in adiposity contribute to the
development of chronic disease in the elderly, or the development of metabolic syndrome
which occurs in 40-70% of the elderly.
Impact of high-fat diets on aspects of aging
High-fat diets (HFD) have been used for many years to study the effects of increased
adiposity, dyslipidemia and insulin resistance in rodents. It has been shown that the
disturbances originated by high-fat feeding closely resemble the metabolic disturbances
observed in humans (Woods et al. 2003). Several different types of HFDs are commonly
utilized in the study of diet-induced obesity and insulin resistance. One problem with this
literature is that all of the effects of these various HFDs (which vary in the amount and
source of dietary fat) have all been summarized as being “HFD effects”. This has inevitably
been source of great variability in the findings reported. Additionally, many studies have
contrasted the effects of HFD to animals fed a standard chow diet, which dramatically
affects the interpretation of findings as compared to using appropriate low fat control diets.
This is because standard chow diets differ in the amount and source of dietary fat, as well as
other dietary components, and therefore do not allow controlled studies on the specific effect
elevated dietary fat has on individual parameters.
Despite the tremendous progress which has been made in our understanding of dietary fat
and obesity/diabetes with using these different HFDs, it is important to point out that
relatively little is currently available in regards to the study of HFDs and brain aging. For
example, studies have not firmly established the ability of HFDs to promote or accelerate
different aspects of brain aging. Additionally, studies have not examined in a comprehensive
manner what specific aspects of perturbed metabolism (high fasting glucose,
hyperinsulemia, elevated adiposity, cholesterol level, fatty acid levels, etc.) may be most
involved in the promotion of brain aging.
In addition to the use of diets, many rodent strains have been utilized as models of obesity,
and the use of these models has contributed strongly to the understanding of obesity
(Kanoski et al. 2007;Wu et al. 2004). In particular, the ob/ob mouse, which is characterized
by an increase in both number and size of adipocytes, and also by its perturbations in leptin
treatment, has been used to test the effects of obesity on the brain (Itateyama et al.
2003;Terao et al. 2008). However, due to the polygenic character of this disorder and the
numerous congenic perturbations observed in these rodent models (ob/ob mice, fa/fa Zucker
rats) they have an obvious limitation in the study of brain aging. Thus, HFD-induced models
of metabolic dysfunction should be considered the best option for studying the effects of
metabolic dysfunction on human brain aging.
HFD can accelerate age-related adiposity
As pointed out above, aging leads to a redistribution of body fat, with a stabilization or
enhancement of visceral fat and fat deposition into tissues such as liver, muscle, and bone.
Similarly, HFD consumption has been also found to increase visceral fat mass (Park et al.
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2001). This increased amount of visceral adipose tissue usually results in elevated
concentrations and flux of circulating free fatty acids into the portal circulation (Bjorntorp
1990), since the abdominal fat has a high lipolytic activity and is very sensitive to adrenergic
stimulation due to the peculiarities of the lipolytic cascade (Wahrenberg et al. 1989). This
elevation of circulating free fatty acids is associated with increased hepatic glucose
production (Ferrannini et al. 1983), reduced hepatic insulin clearance (Svedberg et al. 1990),
decreased peripheral glucose uptake (Ferrannini et al. 1983), and increased very-low-density
lipoprotein-triglyceride synthesis (Kissebah et al. 1976). Thus a higher rate of lipolysis is
able to cause the disturbances in glucose and lipoprotein metabolism associated with diet-
induced obesity. HFD consumption is therefore capable of promoting novel metabolic
perturbations as well as accelerate individual aspects of age-related metabolic disturbances.
HFD can exacerbate peripheral inflammation
HFD-induced metabolic dysfunction has been shown to positively correlate with markers of
acute-phase response such as C-reactive protein (CRP) (Koenig et al. 1999;Mendall et al.
1996) and fibrinogen (Juhan-Vague et al. 1993). Elevated levels of CRP have been
associated with high fasting glucose, high serum lipids, high body mass index (Koenig et al.
1999;Mendall et al. 1996;Yudkin et al. 1999) . It has been shown that chronic, subclinical
inflammation is part of insulin resistance syndrome and that dyslipidemia, abdominal
obesity, low insulin sensitivity and hypertension parallel increasing levels of CRP (Festa et
al. 2000). It is possible that HFD consumption can provoke cytokine secretion to the point it
leads to insulin resistance, and may thereby accelerate age-related processes leading to
insulin resistance (Festa et al. 2000).
Decreased insulin sensitivity may be responsible of the increased CRP expression, since the
physiological effect of insulin on hepatic protein synthesis includes the stimulation of
albumin synthesis and inhibition of fibrinogen synthesis (De Feo et al. 1993). Resistance to
insulin would then be expected to lead to increased synthesis of acute-phase proteins, such
as fibrinogen and CRP. In addition to these mechanisms, HFD via the acceleration of
adipose reactivity may promote a generalized increase in inflammatory signaling as the
result of adipose-derived adipokine signaling throughout the body. All these data indicate
that subclinical inflammation would be expected to be present early in HFD-induced
metabolic dysfunction (such as elevated adiposity and insulin resistance), and thereby link
HFD-induced modulation of metabolic dysfunction to age-related changes in inflammatory
signaling.
Molecular pathways for HFD effects on metabolic dysfunction
Mitochondrial dysfunction—Several studies have related diet-induced metabolic
disturbances with mitochondrial alterations. For example, a decreased expression of genes
involved in mitochondria biogenesis has been observed following HFD consumption
(Handschin and Spiegelman 2006;Nisoli et al. 2007;Shen et al. 2004). Similarly, HFDs have
been demonstrated to decrease the levels of mitochondrial complex 1 activity (Nisoli et al.
2007). Complex I, also known as NADH-ubiquinone oxidoreductase, is a membrane
enzyme complex of the mitochondrial electron transport chain that catalyzes electron
transfer from NADH to ubiquinone thus generating proton motive force. Decreased levels of
this complex will have pronounced deleterious effects on mitochondrial energy-generating
efficiency, which together with an altered biogenesis, would be expected to compromise
energy availability in the aging brain. HFD effects on mitochondria may therefore serve as a
potential mechanism by which metabolic dysfunction induces by HFD consumption
modulates the rates of brain aging.
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Oxidative stress—Oxidative stress is thought to be one of the earliest steps in HFD-
induced pathogenesis (Matsuzawa-Nagata et al. 2008). Reactive oxygen species (ROS) are
normal byproducts of biological processes but are known to be capable of reactivity with
proteins, nucleic acids, and lipids. Mitochondrial-derived ROS are believed to be a major
site of HFD-induced oxidative stress (Cecarini et al. 2007;Lau et al. 2007;Joseph et al.
2005), although studies have also identified a role for NADPH oxidase in HFD induced
oxidative stress (Bruce-Keller et al. 2010). Increased levels of oxidative stress have been
found in animals and humans following HFD-induced metabolic dysfunction (Matsuzawa-
Nagata et al. 2008;Iqbal 2007;Yaffe 2007;Moreira et al. 2008;Furukawa et al.
2004;Urakawa et al. 2003;Diniz et al. 2006;Fridlyand and Philipson 2006;Mantena et al.
2008). Taken together, these data suggest that the HFD consumption may play an important
role in regulating age-related increases in oxidative stress.
Sirtuin signaling—Sirtuins are a family of NAD+-dependent histone/protein deacetylases
involved in a broad range of physiological functions, including control of gene expression,
metabolism, and aging (Bordone and Guarente 2005). Many studies have associated sirtuins
with caloric restriction-mediated health benefits including increased longevity (Blander and
Guarente 2004;Gray and Ekstrom 2001;Smith et al. 2000;Tanner et al. 2000). Because of
the ability of caloric restriction to promote beneficial effects on metabolism and brain aging,
these studies identify a potentially important role for sirtuins in promoting the beneficial
effects of caloric restriction on the brain. Seven distinct sirtuins (Sirt1-Sirt7) have been
described in mammals, being Sirt1 expressed in several tissues and implicated in effects
such as stress resistance, reduced apoptosis, and metabolic changes associated with calorie
restriction (Blander and Guarente 2004).
Almost all Sirt1-deficient animals die during early postnatal development (Chen et al.
2005), with reduced triglycerides, insulin, and blood glucose observed in these same
animals. Such findings further link Sirt1 to metabolic regulation. Sirt1 is also present in
white adipose tissue, where has been shown to reduce adipogenesis and triglyceride
accumulation in the lipid droplets of a cell model of white adipocytes. These observations
have been related to decreased expression of genes involved in fatty acid metabolism, such
as peroxisome proliferator-activated receptors gamma (PPARγ). Additionally, in vivo,
fasting induces Sirt1 and promotes lipolysis by inhibiting PPARγ-mediated fatty acid
trapping. The function of Sirt1 in the release of insulin by pancreatic β cells has also been
studied, and it has been found that reduction of Sirt1 expression in β cell lines promotes a
reduction in insulin secretion (Bordone et al. 2006).
Studies have shown that a modest overexpression of Sirt1 protects hepatic lipid and glucose
metabolism from damage caused by HFDs. Additionally, Sirt1 has been found to be
involved in the protection from metabolic syndrome. Sirt1 activators have been found to be
beneficial for mitochondrial and metabolic function in obese rodents and are currently being
studied as potential treatments for type-2 diabetes (Milne et al. 2007). It has been reported
that moderate Sirt1 overexpression in mice prevents HFD-induced glucose intolerance and
nonalcoholic fatty liver disease (Pfluger et al. 2008). Together, these data raise the
possibility of HFDs mediating their effects on the aging brain in a sirtuin-dependent manner,
although more work in this area is clearly needed.
Evidence for HFD exacerbating brain aging
HFD consumption is thought to induce changes not only in energy metabolism but also in
brain function. Considerable clinical evidence suggests that HFD consumption and the
presence of metabolic dysfunction are sufficient to exacerbate brain aging, promoting the
development of cognitive alterations including dementia (Yaffe 2007;Haan et al.
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2003;Taylor and MacQueen 2007). Moreover, obese adults have shown more severe brain
atrophy than non-obese adults (Ward et al. 2005), further linking HFD consumption to brain
perturbations.
Insulin has been suggested to play important roles in regulating memory, so any disturbance
in insulin signaling would be expected to have a negative impact on memory (Luchsinger et
al. 2004). Some studies have demonstrated that HFDs are able to increase amyloid beta
peptide (Aβ) levels and Aβ-neuropathy in brains of mice exhibiting Alzheimer's disease
(AD) pathology (Ho et al. 2004). Experimental evidence suggests that alterations in insulin
metabolism may influence the onset of AD through their influence on the synthesis and
degradation of Aβ peptides. Moreover, high levels of circulating insulin may also promote
the accumulation of Aβ peptides by directly competing with Aβ for the insulin-degrading
enzyme (IDE), thereby limiting Aβ degradation by IDE. However, whether the risk of AD is
increased in human patients with diabetes mellitus is a matter of some debate. Some studies
have reported that diabetic patients have elevated risk of developing AD (Leibson et al.
1997;Ott et al. 1999;Arvanitakis et al. 2004;Craft et al. 1998). However, several clinical
studies have indicated that diabetes does not seem to be associated to AD (Luchsinger et al.
2004;Tariot et al. 1999;Curb et al. 1999;MacKnight et al. 2002;Akomolafe et al. 2006).
Moreover, almost all neuropathological studies so far have failed to detect any associations
between AD-related pathology and diabetes (Heitner and Dickson 1997;Petrovitch et al.
2000;Peila et al. 2002;Arvanitakis et al. 2006;Janson et al. 2004). Instead, diabetes has been
associated to the presence of cerebral infarcts (Peila et al. 2002;Arvanitakis et al. 2006).
Since diabetes present altered capillary blood vessels in the peripheral vasculature, it is not
surprising that diabetes promotes changes in brain microvasculature. Interestingly, data from
the Framingham study has demonstrated a link between type-2 diabetes and lower cognition
scores (Elias et al. 1997), and hyperglycemia has been found to negatively influence
cognitive impairment in population-based studies (Franceschi et al. 1984;Langan et al.
1991;Messier et al. 1999;Robertson-Tchabo et al. 1986).
Another metabolic disturbance associated with HFD-consumption and obesity is
hypertension which is considered a great risk factor for cerebral stroke (Rosamond et al.
2008). One possible mechanism by which obesity may increase the risk of stroke is via an
alteration in cerebral perfusion. Cerebral perfusion is regulated through active constrictor
and dilator mechanisms and by the physical properties of the cerebral vasculature, such as
myogenic tone and vessel structure. Increased myogenic tone has been reported to occur in
middle and posterior cerebral arteries from spontaneously hypertensive rats, as well as
vasopressin-deficient rat (Dunn et al. 1998;Gonzalez et al. 2008). Additionally, a great body
of evidence has reported vascular remodeling in the cerebral circulation in different models
of hypertension, spontaneously hypertensive rats among them (Dunn et al. 1998;Arribas et
al. 1996;Baumbach and Heistad 1989). The most common changes in hypertensive
populations are mechanical and architectural properties of the cerebral vasculature,
particularly an inward remodeling of the large arteries (Baumbach et al. 1988;Baumbach
and Heistad 1989;Baumbach and Heistad 1988). Inward remodeling not only increases the
risk of flow obstruction but it is also detrimental in ischemic conditions. After ischemia,
brain vessels are near-maximally vasodilated, so reductions in maximum lumen diameter
become a constraint on perfusion. In addition, it is well known that alterations of arterial
pressure cause deleterious changes in vascular structure, as vessels become rigid, wall
thickness can increase and lumen diameter can decrease (Baumbach and Heistad
1989;Heistad et al. 1990), causing an extra impairment of blood flow during ischemia. In
addition, studies carried out in adult obese Zucker rats (OZRs) with moderate hypertension
and severe insulin resistance have demonstrated an increased cerebral vascular myogenic
tone, inward cerebral vascular remodeling, and increased cerebral tissue death after
ischemia/reperfusion injury in these rodents (Osmond et al. 2009). Important to note, young
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OZRs, which are obese and insulin resistant but not yet hypertensive, did not show any of
those deficits (Osmond et al. 2009). Additionally, other studies carried out in leptin deficient
ob/ob mice and also in diet-induced obese mice have shown that obesity worsens the
response to ischemia (Nagai et al. 2007;Terao et al. 2008). All these data together suggest
that obesity together with prolonged moderate hypertension serve as risk factors for cerebral
vascular dysfunction and stroke.
Dyslipidemia is another common disease associated with HFD consumption. More than
50% of the US population older than 20 years old have cholesterol levels of 200 mg/dl or
higher, and more than 18% have levels of 240 mg/dl or higher. The link between
dyslipidemia and having a higher risk of cognitive impairment or dementia is controversial
(Kuo et al. 1998;Wieringa et al. 1997;Lesser et al. 2001;Scacchi et al. 1998). Reduced
levels of high-density lipoprotein (HDL) cholesterol have been reported in some cases of
dementia (Kuo et al. 1998;Wieringa et al. 1997;Muckle and Roy 1985;Kuriyama et al.
1994;Kuriyama et al. 1992;Michikawa 2003;van Exel et al. 2002) but not all cases of
dementia.
Direct evidence for HFD promoting brain pathogenesis
A large body of evidence from rodent and human studies has demonstrated that HFD-
induced metabolic dysfunction promotes cognitive alterations and dementia (Craft
2005;Kumari et al. 2000;Li et al. 2007;Pasinetti et al. 2007;Razay et al. 2007). Different
studies have been performed on rats in order to clarify the influence specific diets may have
on different aspects of cognition. Interestingly, it has been documented that even maternal
HFD consumption sensitizes offspring to the deleterious consequences of HFD (White et al.
2009). Studies carried out in rats have shown that, in agreement with biochemical and
physiological evidence, a diet high in saturated fatty acids can impair learning and memory
functions (Greenwood and Winocur 1990;Granholm et al. 2008). Moreover, direct injection
of triglycerides into the brain has shown to have detrimental consequences for learning and
memory (Farr et al. 2008). In addition, the strong relationship between obesity and cognitive
impairment found in animals (White et al. 2009;Granholm et al. 2008;Baran et al.
2005;Winocur and Greenwood 2005) supporting an association between obesity and deficits
in learning, memory, and executive functioning in human patients (Elias et al. 2003;Elias et
al. 2005). At present, oxidative stress and brain inflammation are thought to play key roles
in HFD-induced cognitive loss, since brain markers of oxidative stress and inflammation
have been found to be increased in mice fed HFD which show clear cognitive impairment
(Pistell et al. 2010;Souza et al. 2007;Zhang et al. 2005). Furthermore, HFD consumption
has been shown to increase age-related oxidative stress in the brain (Mattson et al.
2003;Perry et al. 2003). For example, rodents fed high-fat or high-calorie diets have shown
to have increased levels of oxidative stress (Zhang et al. 2005) and protein oxidation (Souza
et al. 2007) in the brain. However, it is still unclear whether oxidative stress in HFD models
of obesity is the result of obesity per se, or is more related to the associated metabolic
dysfunction. Although there is a clear relation between obesity and brain inflammation, the
real mechanisms whereby HFD contributes to brain inflammation and cognitive impairment
also remain elusive. Certainly, brain function is sensitive to inflammatory pathways and
mediators. For example, IL-1β and IL-6 are able to alter physiologic mechanisms involved
in cognition and memory (Bellinger et al. 1995;Jankowsky and Patterson 1999;Gemma and
Bickford 2007). Adiponectin and leptin, two well known adipokines, could be considered as
important links between obesity, insulin resistance and related inflammatory disorders
(Antuna-Puente et al. 2008;Fantuzzi 2005). Adiponectin has been shown to exhibit
neuroprotective and anti-inflammatory properties in the brain (Chen et al. 2009) and to have
important roles against the development of insulin resistance, dyslipidemia and
atherosclerosis (Rasouli and Kern 2008). Leptin has also been reported to have important
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roles in cognition (Harvey et al. 2005;Oomura et al. 2006) and in the modulation of
inflammatory signaling in microglia (Pinteaux et al. 2007). Among the afferent inputs that
the brain uses to adjust food intake and energy metabolism, leptin is one of the best
understood, supressing food intake and increases energy expenditure (Friedman and Halaas
1998). Studies such as these raise the possibility of roles for leptin in the aging brain that are
independent of leptin effects in the hypothalamus and the regulation of feeding behavior.
There is also reasonable evidence for believing that insulin might also play a role in
mediating the effects of HFD consumption on the brain, since insulin is known to act within
the hippocampus. In vitro studies have shown that insulin can modulate hippocampal
synaptic plasticity (Izumi et al. 2003;van der Heide et al. 2005;Zhao et al. 2004). In
addition, it is also known that hippocampal cognitive performance strongly depends on
glucose supply (Gold 2005;McNay et al. 2000;McNay and Gold 2002), which is regulated
in larger part by peripheral insulin levels. It has been reported that hippocampus of AD
brains have lower levels of glucose utilization and a corresponding impairment in insulin
signaling (Frolich et al. 1998;Hoyer 2004;Steen et al. 2005).
Summary
Considerable evidence suggests a role for metabolic dysfunction as a modulator of brain
aging, and consequently raises the specter of stressors such as HFD consumption as
mediators of accelerated brain aging. In this model HFD consumption promotes a myriad of
metabolic disturbances during aging, which directly and/or indirectly modulate the rate the
brain ages. Of particular interest is the possibility that metabolic dysfunction during aging
(in response to HFD consumption, genetics, physical activity, etc.) accounts for the
considerable variability in the rates of brain aging that are observed in the elderly. Despite
the progress made in this research area, several key questions remain to be answered. For
example, which component(s) of metabolic dysfunction are responsible for the initiation/
propagation of brain aging? How do individual aspects of metabolic dysfunction mediate
neurochemical, structural, and/or functional changes in the aging brain? Answering these
questions will likely contribute to not only our understanding of brain aging, but also to the
development of therapeutic interventions which promote healthy brain aging.
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Figure 1. Interplay between metabolic dysfunction, high fat diets and brain aging
Consumption of a high fat diet (HFD) and the presence of metabolic dysfunction (insulin
resistance, adiposity, etc.) are associated with pathological brain aging. Pathological brain
aging is linked to excessive cognitive decline, high oxidative stress, alterations in brain
structure, and increased inflammatory signaling. In contrast, consumption of a low fat diet,
caloric restriction, and maintenance of metabolic function results in successful brain aging.
The successful brain aging is defined as preserved cognition, decreased oxidative stress,
preserved structure, and reduced inflammatory signaling.
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